NCT02553941 - Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 17, 2016

Primary Completion Date

May 25, 2019

Study Completion Date

November 7, 2019

Conditions

Chronic Myelomonocytic Leukemiade Novo Myelodysplastic SyndromePreviously Treated Myelodysplastic SyndromeRefractory Anemia With Excess Blasts in TransformationSecondary Myelodysplastic Syndrome

Interventions

DRUG

Azacitidine

Given intravenous or subcutaneous

DRUG

Ibrutinib

Given by mouth once daily

Trial Locations (5)

90095

UCLA / Jonsson Comprehensive Cancer Center, Los Angeles

92103

University of California San Diego, San Diego

92868

UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange

94118

University of California, San Francisco, San Francisco

95817

University of California Davis Comprehensive Cancer Center, Sacramento